Search - tctmd.com

Displaying 461 - 480 of 900

Sort: Relevancy | Date

Long-term Absorb BVS Data Continue to Disappoint

News Conference News TCT 2017

Long-term Absorb BVS Data Continue to Disappoint

Michael O'Riordan

October 31, 2017

Live From Denver: TCT 2017, Day One

News Conference News TCT 2017

Live From Denver: TCT 2017, Day One

October 30, 2017

No Late Quality of Life Trade-offs With PCI in Left Main Disease: EXCEL-QOL Substudy

News Conference News TCT 2017

No Late Quality of Life Trade-offs With PCI in Left Main Disease: EXCEL-QOL Substudy

Michael O'Riordan

October 30, 2017

CULPRIT-SHOCK Disputes Benefit of Immediate Multivessel PCI in Patients With Cardiogenic Shock

News Conference News TCT 2017

CULPRIT-SHOCK Disputes Benefit of Immediate Multivessel PCI in Patients With Cardiogenic Shock

October 30, 2017

Fuctional vs. Anatomic Complete Revascularization

Presentation Stanford Coronary Physiology Conference 2017

Fuctional vs. Anatomic Complete Revascularization

Presenter: William F. Fearon

October 28, 2017

Absorb BVS Again Linked to Scaffold Thrombosis at 1 Year and Beyond

News Daily News

Absorb BVS Again Linked to Scaffold Thrombosis at 1 Year and Beyond

Michael O'Riordan

October 17, 2017

Modified Risk Score for ED Chest Pain Patients Reduces Hospital Stays, Lowers Costs

News Daily News

Modified Risk Score for ED Chest Pain Patients Reduces Hospital Stays, Lowers Costs

Michael O'Riordan

October 03, 2017

New Guidelines for Cardiogenic Shock Push for Regionalized Care, More Research

News Daily News

New Guidelines for Cardiogenic Shock Push for Regionalized Care, More Research

September 21, 2017

Study Questions Incremental Benefit of Beta-Blockers After Acute MI

News Daily News

Study Questions Incremental Benefit of Beta-Blockers After Acute MI

Michael O'Riordan

September 21, 2017

More Liberal Definition of Type 2 MI May Misclassify Some Patients

News Daily News

More Liberal Definition of Type 2 MI May Misclassify Some Patients

September 20, 2017

TCTMD’s Top 10 Most Popular Stories for August 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2017

August 31, 2017

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

News Conference News ESC 2017

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

Michael O'Riordan

August 28, 2017

Dual Antithrombotic Approach in Patients With A-fib Undergoing PCI Boosted in RE-DUAL PCI

News Conference News ESC 2017

Dual Antithrombotic Approach in Patients With A-fib Undergoing PCI Boosted in RE-DUAL PCI

August 27, 2017

ESC Updates Guidelines for Treating STEMI Patients

News Conference News ESC 2017

ESC Updates Guidelines for Treating STEMI Patients

Michael O'Riordan

August 27, 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

News Conference News ESC 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Michael O'Riordan

August 27, 2017

CABG Appears Superior to PCI for Patients With Type 1 Diabetes, Multivessel Disease

News Conference News ESC 2017

CABG Appears Superior to PCI for Patients With Type 1 Diabetes, Multivessel Disease

August 26, 2017

Revascularization in Shock: Does it matter?

Presentation CHIP Seattle 2017

Revascularization in Shock: Does it matter?

Presenter: Robert W. Yeh

August 11, 2017

Readmissions After Acute MI Not Only Confined to the Elderly

News Daily News

Readmissions After Acute MI Not Only Confined to the Elderly

Yael L. Maxwell

August 09, 2017

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

News Daily News

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

Michael O'Riordan

August 08, 2017

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

News Daily News

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

Michael O'Riordan

August 04, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.